SL VaxiGen Inc.

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Request demo

SL VaxiGen Inc. - overview

About

Based in Seongnam, South Korea, and founded in 2017, SL VaxiGen Inc. operates as a research and development company dedicated to developing innovative vaccine therapeutics based on complementary platforms. The CEO of the company is the Post-doc fellowship, Harvard Medical School. Before worked in this company, the CFO, Kyeong Ha Lee was the director of Finance Div.

, Genexine. Inc. The company possesses two technologies which are DNA vaccine technology and B. S.

A platform technology. The DNA vaccine technology is a highly efficient vector the company combined the disease-specific multiple antigens and applied antigen engineering technologies such as codon optimization and gene shuffling in efficient expression vector system. The targeting to vaccine-induced CTLs of the company, enable the vaccine-induced CTL (cytotoxic T lymphocyte) to be increased in the course of immune responses. The pipelines of the company include SL-V10, SL-V20, SL-V30, which can be used in infectious diseases and SL-V60 used to cure cancer.

Primary Industry

Biotechnology

Sub Industries

Molecular Science, Genetics & Gene Therapy, Healthcare IT, Therapeutic Devices

Website

www.slvaxigen.com

Company Stage

Early Stage

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.

Request demo